Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes

References

• Gourgari E, Wilhelm EE, Hassanzadeh H, et al. A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data. J Diabetes Complications. 2017 Dec;31(12):1719–1727. PubMed PMID: 28939018.
   PubMed Web of Science ®Google Scholar
• Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med. 1995 Aug;18(4):303–311. PubMed PMID: 8549017
   PubMed Web of Science ®Google Scholar
• van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a cochrane systematic review and meta-analysis. Diabetes Care. 2005 Jan;28(1):154–163. PubMed PMID: 15616251.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Tong Y, Wu T, et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther. 2013 Jun;35(6):880–899. PubMed PMID: 23602502.
   PubMed Web of Science ®Google Scholar
• Dabhi AS, Bhatt NR, Shah MJ. Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res. 2013 Dec;7(12):3023–3027. PubMed PMID: 24551718; PubMed Central PMCID: PMCPMC3919386
   PubMedGoogle Scholar
• Drent ML, Tollefsen AT, van Heusden FH, et al. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Diabetes Nutr Metab. 2002 Jun;15(3):152–159. PubMed PMID: 12173729
   PubMedGoogle Scholar
• Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol. 1998 Apr;35(1):34–40. PubMed PMID: 9625287.
   PubMed Web of Science ®Google Scholar
• Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003639. PubMed PMID: 15846673. DOI:10.1002/14651858.CD003639.pub2.
   PubMed Web of Science ®Google Scholar
• Pan CY, Gao Y, Li GW, et al. [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2009 Apr;48(4):304–307. PubMed PMID: 19576120
   PubMedGoogle Scholar
• Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care. 1994 Jun;17(6):561–566. PubMed PMID: 8082525
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med. 1997 Dec;103(6):483–490. PubMed PMID: 9428831.
   PubMed Web of Science ®Google Scholar
• Vichayanrat A, Ploybutr S, Tunlakit M, et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract. 2002 Feb;55(2):99–103. PubMed PMID: 11796175
   PubMed Web of Science ®Google Scholar
• Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract. 1998 Jul;41(1):49–55. PubMed PMID: 9768372
   PubMed Web of Science ®Google Scholar
• Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes. 1998;106(3):231–233. PubMed PMID: 9710365
   PubMed Web of Science ®Google Scholar
• Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol. 2013 May;4(12):73. PubMed PMID: 23642288; PubMed Central PMCID: PMCPMC3653752.
   PubMed Web of Science ®Google Scholar
• Enc FY, Imeryuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G752–63. PubMed PMID: 11518688.
   PubMed Web of Science ®Google Scholar
• DeLeon MJ, Chandurkar V, Albert SG, et al. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002 May;56(2):101–106. PubMed PMID: 11891017.
   PubMed Web of Science ®Google Scholar
• Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med. 2009 Feb;26(2):187–188. PubMed PMID: 19236625.
   PubMed Web of Science ®Google Scholar
• Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000 Sep;50(1):49–56. PubMed PMID: 10936668.
   PubMed Web of Science ®Google Scholar
• Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care. 2003 Feb;26(2):269–273. PubMed PMID: 12547847.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998 Dec;21(12):2050–2055. PubMed PMID: 9839093.
   PubMed Web of Science ®Google Scholar
• Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med. 1999 Sep;16(9):755–761. PubMed PMID: 10510952
   PubMed Web of Science ®Google Scholar
• Rosak C, Haupt E, Walter T, et al. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab. 2002 Jun;15(3):143–151. PubMed PMID: 12173728
   PubMedGoogle Scholar
• Chiasson JL, Naditch L, Miglitol Canadian University Investigator G. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001 Jun;24(6):989–994. PubMed PMID: 11375358.
   PubMed Web of Science ®Google Scholar
• Jayaram S, Hariharan RS, Madhavan R, et al. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. J Assoc Physicians India. 2010 Nov;58:679–82, 687. PubMed PMID: 21510461
   PubMedGoogle Scholar
• Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract. 2001 Jun;52(3):193–204. PubMed PMID: 11323089.
   PubMed Web of Science ®Google Scholar
• Saito N, Sakai H, Suzuki S, et al. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. J Int Med Res. 1998 Oct-Nov;26(5):219–232. PubMed PMID: 9924706.
   PubMed Web of Science ®Google Scholar
• Kusunoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J. 2013;60(4):431–439. PubMed PMID: 23220949
   PubMed Web of Science ®Google Scholar
• Takahara M, Shiraiwa T, Katakami N, et al. Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocr J. 2014;61(5):447–456. PubMed PMID: 24561488
   PubMed Web of Science ®Google Scholar
• Abe M, Kikuchi F, Kaizu K, et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol. 2007 Nov;68(5):287–294. PubMed PMID: 18044260.
   PubMed Web of Science ®Google Scholar
• Schnell O, Mertes G, Standl E, et al. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab. 2007 Nov;9(6):853–858. PubMed PMID: 17924867.
   PubMed Web of Science ®Google Scholar
• Yang G, Li C, Gong Y, et al. A prospective, randomized, open-label study comparing the efficacy and safety of preprandial and prandial insulin in combination with acarbose in elderly, insulin-requiring patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013 Jun;15(6):513–519. PubMed PMID: 23530576.
   PubMed Web of Science ®Google Scholar
• Josse RG, Chiasson JL, Ryan EA, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003 Jan;59(1):37–42. PubMed PMID: 12482640.
   PubMed Web of Science ®Google Scholar
• Mitrakou A, Tountas N, Raptis AE, et al. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabet Med. 1998 Aug;15(8):657–660. PubMed PMID: 9702468.
   PubMed Web of Science ®Google Scholar
• Matsumura M, Monden T, Miyashita Y, et al. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660–666. PubMed PMID: 19568704.
   PubMed Web of Science ®Google Scholar
• Osonoi T, Saito M, Mochizuki K, et al. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism. 2010 Dec;59(12):1816–1822. PubMed PMID: 20667563.
   PubMed Web of Science ®Google Scholar
• Weng J, Soegondo S, Schnell O, et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes Metab Res Rev. 2015 Feb;31(2):155–167. PubMed PMID: 25044702.
   PubMed Web of Science ®Google Scholar
• Philip E, Sundaram ML, Das R, et al. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab. 2013 Dec;17(Suppl 3):S674–9. PubMed PMID: 24910836; PubMed Central PMCID: PMCPMC4046615.
   PubMedGoogle Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003 Jul 23;290(4):486–494. PubMed PMID: 12876091.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004 Jan;25(1):10–16. PubMed PMID: 14683737.
   PubMed Web of Science ®Google Scholar
• Hsu PF, Sung SH, Cheng HM, et al. Cardiovascular benefits of acarbose vs sulfonylureas in patients with type 2 diabetes treated with metformin. J Clin Endocrinol Metab. 2018 Oct 1;103(10):3611–3619. PubMed PMID: 30113697.
   PubMed Web of Science ®Google Scholar
• Hirano M, Nakamura T, Obata JE, et al. Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes. Circ J. 2012;76(6):1452–1460. PubMed PMID: 22453003
   PubMed Web of Science ®Google Scholar
• Patel YR, Kirkman MS, Considine RV, et al. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. Diabetes Metab Res Rev. 2013 Oct;29(7):582–591. PubMed PMID: 23908125; PubMed Central PMCID: PMCPMC4062388.
   PubMed Web of Science ®Google Scholar
• Oyama T, Saiki A, Endoh K, et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb. 2008 Jun;15(3):154–159. PubMed PMID: 18603822.
   PubMed Web of Science ®Google Scholar
• Koyasu M, Ishii H, Watarai M, et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Ther. 2010 Aug;32(9):1610–1617. PubMed PMID: 20974318.
   PubMed Web of Science ®Google Scholar
• Uzui H, Nakano A, Mitsuke Y, et al. Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus. J Diabetes Investig. 2011 Apr 7;2(2):148–153. PubMed PMID: 24843474; PubMed Central PMCID: PMCPMC4015543.
   PubMed Web of Science ®Google Scholar
• Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Nov;5(11):877–886. PubMed PMID: 28917545.
   PubMed Web of Science ®Google Scholar
• Decode Study Group tEDEG. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001 Feb 12;161(3):397–405. PubMed PMID: 11176766.
   PubMedGoogle Scholar
• Aoki K, Sato H, Terauchi Y. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones. Endocr J. 2019 May 28;66(5):395–401. PubMed PMID: 31019154.
   PubMed Web of Science ®Google Scholar